Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Takehiko Kawanishi"'
Autor:
Takehiko Kawanishi, Koichiro Yoneyama, Hiroyuki Fukase, Naoki Kotani, Tohru Shimuta, Nobuhiko Kawakami
Publikováno v:
Clinical Pharmacology in Drug Development
Emicizumab (ACE910) is a bispecific antibody that is a novel, subcutaneously injectable treatment for patients with hemophilia A. This study assessed the relative bioavailability of emicizumab between old and new drug products (DPs) and among 3 commo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d7955a1c3f55840eb066b8a6cf536d3
https://doi.org/10.1002/cpdd.617
https://doi.org/10.1002/cpdd.617
Autor:
Ghassan K. Abou-Alfa, Takehiko Kawanishi, Norihisa Ohishi, Mikiko Nakamura, Chao Xu, Ya-Chi Chen, Ruey-min Lee, Satofumi Iida, Toshihiko Ohtomo, Cheikh Diack
Publikováno v:
British Journal of Clinical Pharmacology. 84:944-951
Aims Codrituzumab (GC33) is a recombinant, humanized mAb that binds to glypican-3 (GPC3), an oncofetal protein highly expressed in hepatocellular carcinoma (HCC). This investigation aimed to identify clinically relevant factors that may affect the ov
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a63d9fac220809ff306179b3fa5845a1
https://doi.org/10.1111/bcp.13530
https://doi.org/10.1111/bcp.13530
Autor:
Takehiko Kawanishi, Masanobu Nishidate, Kaname Yamamoto, Chinami Masuda, Hiroaki Aikawa, Mitsuhiro Hayashi, Akinobu Hamada
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-10 (2017)
Scientific Reports
Scientific Reports
Combination therapy of erlotinib plus bevacizumab improves progression-free survival of patients with epidermal growth factor receptor–mutated (EGFR-mutated) advanced non–small-cell lung cancer (NSCLC) compared with erlotinib alone. Although impr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::267ac532a9cf7855fb9f45cbdf944ab0
http://link.springer.com/article/10.1038/s41598-017-17211-6
http://link.springer.com/article/10.1038/s41598-017-17211-6
Autor:
Koichiro Yoneyama, Christophe Schmitt, Naoki Kotani, Takehiko Kawanishi, Gallia G. Levy, Ryu Kasai, Satofumi Iida, Midori Shima
Publikováno v:
Clinical Pharmacokinetics
Background Emicizumab (ACE910) is a bispecific antibody mimicking the cofactor function of activated coagulation factor VIII. In phase I–I/II studies, emicizumab reduced the bleeding frequency in patients with severe hemophilia A, regardless of the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50b97d57397273c2950611498ff5a73e
https://pubmed.ncbi.nlm.nih.gov/29214439
https://pubmed.ncbi.nlm.nih.gov/29214439
Autor:
Mikiko, Nakamura, Chao, Xu, Cheikh, Diack, Norihisa, Ohishi, Ruey-Min, Lee, Satofumi, Iida, Takehiko, Kawanishi, Toshihiko, Ohtomo, Ghassan K, Abou-Alfa, Ya-Chi, Chen
Publikováno v:
British journal of clinical pharmacology. 84(5)
AIMS: Codrituzumab (GC33) is a recombinant, humanized mAb that binds to glypican‐3 (GPC3), an oncofetal protein highly expressed in hepatocellular carcinoma (HCC). This investigation aimed to identify clinically relevant factors that may affect the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::843124b866db4624a417477c60696099
https://pubmed.ncbi.nlm.nih.gov/29381229
https://pubmed.ncbi.nlm.nih.gov/29381229
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics
Ibandronate is a drug widely used outside Japan for the treatment of osteoporosis. It is available in formulations for intermittent intravenous (i.v.) administration and for intermittent (once monthly) oral administration. Ibandronate was recently ap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b1fd007e97c6ba5f8946ea31f137cea
https://doi.org/10.1007/s13318-014-0242-5
https://doi.org/10.1007/s13318-014-0242-5
Publikováno v:
Journal of Pharmacy and Pharmacology. 65:1168-1178
Objectives TP300 is a novel topoisomerase I inhibitor with neutropenia as a significant toxicity. We developed and evaluated a pharmacokinetic–pharmacodynamic (PK-PD) model, using data from Phase I and II trials to predict neutrophil decrease in pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62d91ac60ac57bc575901265d0a573f2
https://doi.org/10.1111/jphp.12065
https://doi.org/10.1111/jphp.12065
Publikováno v:
Drug Metabolism and Pharmacokinetics. 27:614-620
Summary: Peg-interferon-alpha-2a (PEG-IFN) has been used all over the world including Japan as the standard of care for chronic hepatitis C (CHC). PEG-IFN causes platelet count decrease, while CHC patients with compensated liver cirrhosis have a low
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed38c27761b87ea27434f1ecd1df3e6b
https://doi.org/10.2133/dmpk.dmpk-11-rg-148
https://doi.org/10.2133/dmpk.dmpk-11-rg-148
Publikováno v:
Journal of Pharmacy and Pharmacology. 63:65-72
Objectives The objective of this study was to build a ceftriaxone population pharmacokinetic model for Japanese paediatric patients and to examine the dosing regimen of ceftriaxone based on pharmacokinetic/pharmacodynamic (PK/PD) analysis. Methods Th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6022ed36db074ccbcd68ba9a8f0be975
https://doi.org/10.1111/j.2042-7158.2010.01179.x
https://doi.org/10.1111/j.2042-7158.2010.01179.x
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics. 34:107-115
Objective: By using a population pharmacokinetic analysis method, we predicted the efficacy of Ceftriaxone (CTRX) based on the pharmacokinetics of CTRX in Japanese adults and the sensitivity of infective organisms to CTRX in 2004. In addition, we cla
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::990c3bc313935f2cba1f77105cd12faa
https://doi.org/10.1007/bf03191159
https://doi.org/10.1007/bf03191159